Royal London Asset Management Ltd. Lowers Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Royal London Asset Management Ltd. lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 88,154 shares of the company’s stock after selling 14,918 shares during the quarter. Royal London Asset Management Ltd. owned approximately 0.11% of IDEXX Laboratories worth $36,446,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in IDXX. FSA Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $30,000. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $31,000. Kestra Investment Management LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $38,000. Finally, Crews Bank & Trust purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $41,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.4 %

Shares of IDEXX Laboratories stock opened at $420.62 on Friday. The company has a market cap of $34.21 billion, a P/E ratio of 39.42, a PEG ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88. The firm has a fifty day moving average of $437.30 and a two-hundred day moving average of $445.53.

Analyst Ratings Changes

Several brokerages have recently weighed in on IDXX. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Bank of America lifted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Piper Sandler lifted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Finally, StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, March 15th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.